Abstract
Background Prognostic biomarkers for patients admitted for a myocardial infarction (MI) episode are of great interest for risk stratification and follow-up care after discharge. Multi-omics analysis is a standard approach for the discovery of diagnostic and prognostic biomarkers, but few studies have evaluated the prognostic potential of molecular markers in combination with echocardiographic imaging variables.
Methods We measured the plasma proteome and lipidome in patients discharged from an acute MI and followed for secondary outcomes in New Zealand for a median time of 4.85 years (CDCS, N=741 for network inference, N=464 for predictive analysis) and in Singapore for a median time of 2.0 years (IMMACULATE, N=190 for validation). Using a network-based integrative analysis framework iOmicsPASS+, we mapped proteins, lipids, echocardiographic imaging variables and clinical biomarkers to a unified network and identified predictive subnetwork signatures of major adverse cardiac events (MACE) and heart failure hospitalization (HFH) in CDCS, with validation in IMMACULATE.
Results Specific plasma proteins and lipids showed direct connections to cardiac imaging variables in the network. The gold standard biomarker, NT-proBNP, remained one of the best prognostic marker of MACE and HFH, but a number of plasma proteins involved in extracellular matrix organization, chemotaxis, inflammation, and apoptosis were also strong predictors of both outcomes. Hub proteins of subnetwork signatures were enriched in the heart, arteries, kidneys, liver and lungs. BMP10, CAPG, EFEMP1, FSTL3, RSPO4, and RELT were those directly connected to the echocardiographic variables and natriuretic peptides. In particular, EFEMP1 and FSTL3 in combination with diastolic function (E/e’) were strongly predictive of HFH in both CDCS (AUC 0.78, 95%CI 0.72-0.83) and IMMACULATE (AUC 0.72, 0.61-0.84).
Conclusions Our integrative analysis revealed competing signatures beyond established biomarkers of post-MI HFH, comprised of plasma proteins correlated with impaired diastolic function after the primary MI episode.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported in part by grants from National Medical Research Council of Singapore (CIRG17may014 and MOH-000280 to MYC), from New Zealand: The Coronary Disease Cohort Study was funded by the Health Research Council of New Zealand (Program Grants 02/152, 08/070, 11/1070); National Heart Foundation of New Zealand; New Zealand Lotteries Grant Board; Foundation for Research, Science and Technology, and the Christchurch Heart Institute Trust, and National Medical Research Council of Singapore (to AMR). AMR holds the NZ Heart Foundation Chair of Cardiovascular Studies; the National University of Singapore via the Life Sciences Institute (LSI) (to MRW), National Research Foundation (NRFI2015-05, NRFSBP-P4 to MRW) and A*STAR (I1901E0040 to MRW); Singapore Ministry of Education (MOE2016/T2/1/001, NMRC/CG/M009/2017, MOE2018/T2/2/058, MOE-T2EP20121-0018 to HC).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The CDCS study was approved by the New Zealand Multi-region Ethics Committee CTY-02-02-018 and all participants gave written informed consent, and the IMMACULATE study was approved by the institutional review board and the ethics committee at Singapore National Healthcare Group Domain Specific Review Board DSRB 2013-00248 and 2013-00635
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Disclosures: Authors have no conflict of interest to declare.
Data Availability
iOmicsPASS+ is publicly available as an open-source R package in the GitHub repository (https://github.com/cssblab/iOmicsPASSplus). The proteomic and lipidomic data in support of the findings of this study is available at https://github.com/Hiromikwl/Data_iOP. Patient-level clinical records, including echocardiographic imaging variables and clinical biomarkers, can be shared after reasonable preliminary discussion and agreement with both corresponding authors due to ethics and privacy concerns.
